Keywords: myriad, mpc-0920, performs, well, ph, usa-based, biopharmaceutcal

Myriad's MPC-0920 performs well at Ph I

Article | 04 February 2008

Print This

USA-based biopharmaceutcal firm Myriad Genetics has announced the completion of a Phase I trial of MPC-0920, its candidate oral direct ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in